Switch to:
Also traded in: Germany, Mexico, UK, USA
» Details

Insider Trades

Latest Guru Trades with SHPGF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:BIIB, OTCPK:CSLLY, NAS:REGN, NAS:ALXN, OTCPK:ALIOY, NAS:INCY, NAS:VRTX, OTCPK:NONOF, NAS:GILD, NAS:BMRN, OTCPK:GIKLY, OTCPK:UCBJY, NAS:CELG, OTCPK:GMXAY, OTCPK:NVZMY, NAS:TSRO, NAS:SGEN, NAS:ALKS, NAS:JAZZ, NAS:UTHR » details
Traded in other countries:S7E.Germany, SHPG N.Mexico, SHP.UK, SHPG.USA,
Shire PLC is a specialty biopharmaceutical company that focuses on developing and marketing specialty medicines that address unmet patient needs.

Shire PLC is a biotech company incorporated and registered in Jersey on January 28, 2008. The Company is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of medicines to meet unmet patient needs. Its Products include FIRAZYR, LDX, NATPAR, SHP609, GATTEX, INTUNIV, TYVENSE, VENVANSE, OBIZUR, HEMOFIL, FOZNOL among others. The Company develops products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a franchise in Oncology.

Ratios

vs
industry
vs
history
P/E(ttm) 120.68
SHPGF's P/E(ttm) is ranked lower than
89% of the 277 Companies
in the Global Biotechnology industry.

( Industry Median: 27.60 vs. SHPGF: 120.68 )
Ranked among companies with meaningful P/E(ttm) only.
SHPGF' s P/E(ttm) Range Over the Past 10 Years
Min: 12.4  Med: 26.35 Max: 162.3
Current: 120.68
12.4
162.3
Forward P/E 11.10
SHPGF's Forward P/E is ranked higher than
81% of the 75 Companies
in the Global Biotechnology industry.

( Industry Median: 19.72 vs. SHPGF: 11.10 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 72.05
SHPGF's PE(NRI) is ranked lower than
78% of the 251 Companies
in the Global Biotechnology industry.

( Industry Median: 27.87 vs. SHPGF: 72.05 )
Ranked among companies with meaningful PE(NRI) only.
SHPGF' s PE(NRI) Range Over the Past 10 Years
Min: 12.87  Med: 23.28 Max: 106.93
Current: 72.05
12.87
106.93
Price/Owner Earnings (ttm) 29.83
SHPGF's Price/Owner Earnings (ttm) is ranked higher than
50% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. SHPGF: 29.83 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
SHPGF' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 11.33  Med: 24.33 Max: 72.9
Current: 29.83
11.33
72.9
P/B 1.88
SHPGF's P/B is ranked higher than
76% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. SHPGF: 1.88 )
Ranked among companies with meaningful P/B only.
SHPGF' s P/B Range Over the Past 10 Years
Min: 1.7  Med: 5.48 Max: 14.19
Current: 1.88
1.7
14.19
P/S 4.47
SHPGF's P/S is ranked higher than
73% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. SHPGF: 4.47 )
Ranked among companies with meaningful P/S only.
SHPGF' s P/S Range Over the Past 10 Years
Min: 2.25  Med: 4.65 Max: 9.24
Current: 4.47
2.25
9.24
POCF 19.09
SHPGF's POCF is ranked higher than
54% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. SHPGF: 19.09 )
Ranked among companies with meaningful POCF only.
SHPGF' s POCF Range Over the Past 10 Years
Min: 7.66  Med: 17.16 Max: 27
Current: 19.09
7.66
27
EV-to-EBIT 85.88
SHPGF's EV-to-EBIT is ranked lower than
89% of the 284 Companies
in the Global Biotechnology industry.

( Industry Median: 19.01 vs. SHPGF: 85.88 )
Ranked among companies with meaningful EV-to-EBIT only.
SHPGF' s EV-to-EBIT Range Over the Past 10 Years
Min: -16.1  Med: 16.9 Max: 173.7
Current: 85.88
-16.1
173.7
EV-to-EBITDA 23.14
SHPGF's EV-to-EBITDA is ranked lower than
61% of the 307 Companies
in the Global Biotechnology industry.

( Industry Median: 19.22 vs. SHPGF: 23.14 )
Ranked among companies with meaningful EV-to-EBITDA only.
SHPGF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -19.6  Med: 13.55 Max: 33.2
Current: 23.14
-19.6
33.2
PEG 3.81
SHPGF's PEG is ranked lower than
67% of the 98 Companies
in the Global Biotechnology industry.

( Industry Median: 2.11 vs. SHPGF: 3.81 )
Ranked among companies with meaningful PEG only.
SHPGF' s PEG Range Over the Past 10 Years
Min: 0.47  Med: 1.11 Max: 4.43
Current: 3.81
0.47
4.43
Shiller P/E 58.01
SHPGF's Shiller P/E is ranked lower than
53% of the 55 Companies
in the Global Biotechnology industry.

( Industry Median: 47.42 vs. SHPGF: 58.01 )
Ranked among companies with meaningful Shiller P/E only.
SHPGF' s Shiller P/E Range Over the Past 10 Years
Min: 42.92  Med: 100.32 Max: 469
Current: 58.01
42.92
469
Current Ratio 0.97
SHPGF's Current Ratio is ranked lower than
88% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. SHPGF: 0.97 )
Ranked among companies with meaningful Current Ratio only.
SHPGF' s Current Ratio Range Over the Past 10 Years
Min: 0.61  Med: 1.54 Max: 7.07
Current: 0.97
0.61
7.07
Quick Ratio 0.51
SHPGF's Quick Ratio is ranked lower than
91% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. SHPGF: 0.51 )
Ranked among companies with meaningful Quick Ratio only.
SHPGF' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 1.35 Max: 6.9
Current: 0.51
0.44
6.9
Days Inventory 291.59
SHPGF's Days Inventory is ranked lower than
84% of the 439 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. SHPGF: 291.59 )
Ranked among companies with meaningful Days Inventory only.
SHPGF' s Days Inventory Range Over the Past 10 Years
Min: 126.5  Med: 189.11 Max: 291.59
Current: 291.59
126.5
291.59
Days Sales Outstanding 89.10
SHPGF's Days Sales Outstanding is ranked lower than
67% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. SHPGF: 89.10 )
Ranked among companies with meaningful Days Sales Outstanding only.
SHPGF' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.71  Med: 69.72 Max: 89.1
Current: 89.1
47.71
89.1

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.44
SHPGF's Dividend Yield is ranked lower than
88% of the 222 Companies
in the Global Biotechnology industry.

( Industry Median: 1.23 vs. SHPGF: 0.44 )
Ranked among companies with meaningful Dividend Yield only.
SHPGF' s Dividend Yield Range Over the Past 10 Years
Min: 0.23  Med: 0.41 Max: 0.7
Current: 0.44
0.23
0.7
Dividend Payout 0.41
SHPGF's Dividend Payout is ranked lower than
58% of the 126 Companies
in the Global Biotechnology industry.

( Industry Median: 0.32 vs. SHPGF: 0.41 )
Ranked among companies with meaningful Dividend Payout only.
SHPGF' s Dividend Payout Range Over the Past 10 Years
Min: 0.04  Med: 0.1 Max: 0.41
Current: 0.41
0.04
0.41
Dividend Growth (3y) 26.40
SHPGF's Dividend Growth (3y) is ranked higher than
81% of the 88 Companies
in the Global Biotechnology industry.

( Industry Median: 7.70 vs. SHPGF: 26.40 )
Ranked among companies with meaningful Dividend Growth (3y) only.
SHPGF' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 0  Med: 15.65 Max: 57.8
Current: 26.4
0
57.8
Forward Dividend Yield 0.44
SHPGF's Forward Dividend Yield is ranked lower than
67% of the 212 Companies
in the Global Biotechnology industry.

( Industry Median: 1.38 vs. SHPGF: 0.44 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 1.07
SHPGF's Yield on cost (5-Year) is ranked lower than
70% of the 281 Companies
in the Global Biotechnology industry.

( Industry Median: 1.71 vs. SHPGF: 1.07 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
SHPGF' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.56  Med: 0.99 Max: 1.7
Current: 1.07
0.56
1.7
3-Year Average Share Buyback Ratio -14.80
SHPGF's 3-Year Average Share Buyback Ratio is ranked lower than
60% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. SHPGF: -14.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
SHPGF' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -50.3  Med: -2.15 Max: 0.4
Current: -14.8
-50.3
0.4

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.02
SHPGF's Price/Projected FCF is ranked higher than
67% of the 174 Companies
in the Global Biotechnology industry.

( Industry Median: 3.31 vs. SHPGF: 2.02 )
Ranked among companies with meaningful Price/Projected FCF only.
SHPGF' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.16  Med: 1.96 Max: 2.94
Current: 2.02
1.16
2.94
Price/Median PS Value 0.96
SHPGF's Price/Median PS Value is ranked higher than
51% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. SHPGF: 0.96 )
Ranked among companies with meaningful Price/Median PS Value only.
SHPGF' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.67  Med: 1.01 Max: 2.69
Current: 0.96
0.67
2.69
Price/Peter Lynch Fair Value 3.64
SHPGF's Price/Peter Lynch Fair Value is ranked lower than
74% of the 72 Companies
in the Global Biotechnology industry.

( Industry Median: 1.56 vs. SHPGF: 3.64 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
SHPGF' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 0.64  Med: 1.35 Max: 3.64
Current: 3.64
0.64
3.64
Earnings Yield (Greenblatt) (%) 1.20
SHPGF's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. SHPGF: 1.20 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SHPGF' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.6  Med: 5.5 Max: 8.4
Current: 1.2
0.6
8.4
Forward Rate of Return (Yacktman) (%) 20.33
SHPGF's Forward Rate of Return (Yacktman) (%) is ranked higher than
57% of the 122 Companies
in the Global Biotechnology industry.

( Industry Median: 15.82 vs. SHPGF: 20.33 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
SHPGF' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 1.5  Med: 2.4 Max: 28.9
Current: 20.33
1.5
28.9

More Statistics

Revenue (TTM) (Mil) $11,397
EPS (TTM) $ 0.54
Beta1.81
Short Percentage of Float0.00%
52-Week Range $50.74 - 68.67
Shares Outstanding (Mil)904.60

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 15,335 16,689 16,681
EPS ($) 5.28 6.19 6.43
EPS w/o NRI ($) 5.28 6.19 6.43
EPS Growth Rate
(3Y to 5Y Estimate)
12.71%
Dividends Per Share ($) 0.41 0.61
» More Articles for SHPGF

Headlines

Articles On GuruFocus.com
Keeley All Cap Value Fund Comments on Shire Jan 27 2017 
KEELEY All Cap Value Fund 4th Quarter Commentary Jan 27 2017 
Third Avenue Value Fund Buys 2 Stocks and Adds to 2 Positions in Q4 Dec 23 2016 
Julian Robertson Sells Delta Air Lines, Alphabet Dec 07 2016 
John Paulson's Largest 3rd Quarter Trades Dec 01 2016 
Momenta Pharmaceuticals Announces Positive Results for Humira Biosimilar Nov 30 2016 
Samuel Isaly Makes 9 New Buys in 3rd Quarter Nov 04 2016 
Martin Whitman's Top Recent Investments Oct 12 2016 
John Paulson’s Health Care Picks Plunge in Flat Year for Sector Oct 06 2016 
Whitman's Third Avenue Buys 3 Pharma Stocks in 3rd Quarter Sep 27 2016 

More From Other Websites
Shire Plc :SHPGF-US: Earnings Analysis: Q4, 2016 By the Numbers : February 21, 2017 Feb 21 2017
Shire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View Feb 17 2017
Drugmaker Shire Tops Q4 Views; Stock Pops To Six-Week High Feb 16 2017
[$$] Shire beats expectations on back of strong sales Feb 16 2017
Is this the FTSE 100’s top growth stock? Feb 16 2017
Shire beats Street 4Q forecasts Feb 16 2017
Shire beats Street 4Q forecasts Feb 16 2017
Shire Beats Full-Year Earnings Estimates, Sees Robust 2017 Growth Feb 16 2017
FTC says Shire unit used illegal tactics to block generic competition Feb 07 2017
Should you buy or sell AstraZeneca plc after FY sales fall 5%? Feb 02 2017
Shire Plc breached its 50 day moving average in a Bullish Manner : SHPGF-US : February 2, 2017 Feb 02 2017
Shire's (SHPG) ADHD Candidate's NDA Accepted by FDA Jan 20 2017
Is Shire plc a Great Stock for Value Investors? Jan 19 2017
Lawsuit accuses Shire of monopolizing market for ADHD drug Jan 12 2017
PRESS DIGEST- Financial Times - Jan 12 Jan 11 2017
Mylan, other pharmaceutical firms see stocks decline after Trump comments Jan 11 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK